Currently, two innovators are dominating the $50 billion market : Novo Nordisk’s Ozempic or Wegovy (Semaglutide) and Eli ...

One shipment of suspected counterfeit Wegovy was hidden inside a Mickey Mouse puzzle for ... FDA has not approved any generic versions of semaglutide." Eli Lilly, makers of Mounjaro and Zepbound, also ...

Why Novo Nordisk and Eli Lilly are giving totally different reads on the markets for GLP-1 drugs like Wegovy and Zepbound. To catch full episodes of all The Motley Fool's free podcasts, check out our ...

In the study, 33.4% of patients taking Wegovy were admitted, compared to about 37% in the placebo cohort. Use of the weight loss drug was also linked to shorter hospital stays. Eli Lilly and Novo ...

Novo Nordisk's (NVO) third-quarter earnings were solid enough to soothe investor jitters and turn the market's attention toward upcoming trial results for a potentially game-changing new weight-loss ...

The Mounjaro manufacturer, Eli Lilly, said patient safety was the company’s top priority ... Due to the soaring demand for ...

In October, the FDA removed Mounjaro and Zepbound—the diabetes and obesity GLP-1 drugs made by Eli Lilly—from the shortage ...

Emergent BioSolutions' Q3 earnings report drives 20% surge in share price, reflecting market optimism. See why award a ...

Scientists comment on the risks and benefits of tirzepatide (Mounjaro) after a UK death linked to the drug. Prof Naveed Sattar, Professor of Cardiometabolic Medicine/Honorary Consultant, University of ...

Eli Lilly Just Hit a Milestone That Disappointed. Here's Why You Should Still Buy the Stock.